Global (United States, European Union and China) Automation in Biopharmaceutical Market Research Report 2019-2025

2 Global Automation in Biopharmaceutical Quarterly Market Size Analysis

• 2.1 Automation in Biopharmaceutical Business Impact Assessment - COVID-19
  • 2.1.1 Global Automation in Biopharmaceutical Market Size, Pre-COVID-19 and Post- COVID-19 Comparison, 2015-2026
• 2.2 Global Automation in Biopharmaceutical Quarterly Market Size 2020-2021
• 2.3 COVID-19-Driven Market Dynamics and Factor Analysis
  • 2.3.1 Drivers
  • 2.3.2 Restraints
  • 2.3.3 Opportunities
  • 2.3.4 Challenges

3 Quarterly Competitive Assessment, 2020

• 3.1 By Players, Global Automation in Biopharmaceutical Quarterly Market Size, 2019 VS 2020
• 3.2 By Players, Automation in Biopharmaceutical Headquarters and Area Served
• 3.3 Date of Key Players Enter into Automation in Biopharmaceutical Market
• 3.4 Key Players Automation in Biopharmaceutical Product Offered
• 3.5 Mergers & Acquisitions, Expansion Plans

4 Impact of Covid-19 on Automation in Biopharmaceutical Segments, By Type

• 4.1 Introduction
  • 1.4.1 Clinical Stage Automation
  • 1.4.2 Drug Discovery Stage Automation
• 4.2 By Type, Global Automation in Biopharmaceutical Market Size, 2019-2021

5 Impact of Covid-19 on Automation in Biopharmaceutical Segments, By Application

• 5.1 Overview
  • 5.5.1 Research and Development
  • 5.5.2 Clinical
• 5.2 By Application, Global Automation in Biopharmaceutical Market Size, 2019-2021
  • 5.2.1 By Application, Global Automation in Biopharmaceutical Market Size by Application, 2019-2021

6 Geographic Analysis

• 6.1 Introduction
• 6.2 North America
  • 6.2.1 Macroeconomic Indicators of US
  • 6.2.2 US
  • 6.2.3 Canada
• 6.3 Europe
  • 6.3.1 Macroeconomic Indicators of Europe
  • 6.3.2 Germany
  • 6.3.3 France
  • 6.3.4 UK
  • 6.3.5 Italy
• 6.4 Asia-Pacific
  • 6.4.1 Macroeconomic Indicators of Asia-Pacific
  • 6.4.2 China
  • 6.4.3 Japan
  • 6.4.4 South Korea
  • 6.4.5 India
  • 6.4.6 ASEAN
• 6.5 Rest of World
  • 6.5.1 Latin America
  • 6.5.2 Middle East and Africa

7 Company Profiles

• 7.1 Danaher
  • 7.1.1 Danaher Business Overview
  • 7.1.2 Danaher Automation in Biopharmaceutical Quarterly Revenue, 2020
  • 7.1.3 Danaher Automation in Biopharmaceutical Product Introduction
  • 7.1.4 Danaher Response to COVID-19 and Related Developments
• 7.2 GE
  • 7.2.1 GE Business Overview
  • 7.2.2 GE Automation in Biopharmaceutical Quarterly Revenue, 2020
  • 7.2.3 GE Automation in Biopharmaceutical Product Introduction
  • 7.2.4 GE Response to COVID-19 and Related Developments
• 7.3 PerkinElmer
  • 7.3.1 PerkinElmer Business Overview
  • 7.3.2 PerkinElmer Automation in Biopharmaceutical Quarterly Revenue, 2020
  • 7.3.3 PerkinElmer Automation in Biopharmaceutical Product Introduction
  • 7.3.4 PerkinElmer Response to COVID-19 and Related Developments
• 7.4 Tecan Trading
  • 7.4.1 Tecan Trading Business Overview
  • 7.4.2 Tecan Trading Automation in Biopharmaceutical Quarterly Revenue, 2020
  • 7.4.3 Tecan Trading Automation in Biopharmaceutical Product Introduction
  • 7.4.4 Tecan Trading Response to COVID-19 and Related Developments
• 7.5 Thermo Fisher Scientific
  • 7.5.1 Thermo Fisher Scientific Business Overview
  • 7.5.2 Thermo Fisher Scientific Automation in Biopharmaceutical Quarterly Revenue, 2020
  • 7.5.3 Thermo Fisher Scientific Automation in Biopharmaceutical Product Introduction
  • 7.5.4 Thermo Fisher Scientific Response to COVID-19 and Related Developments
• 7.6 Bruker
  • 7.6.1 Bruker Business Overview
  • 7.6.2 Bruker Automation in Biopharmaceutical Quarterly Revenue, 2020
  • 7.6.3 Bruker Automation in Biopharmaceutical Product Introduction
  • 7.6.4 Bruker Response to COVID-19 and Related Developments
• 7.7 Peak Analysis and Automation
  • 7.7.1 Peak Analysis and Automation Business Overview
  • 7.7.2 Peak Analysis and Automation Automation in Biopharmaceutical Quarterly Revenue, 2020
  • 7.7.3 Peak Analysis and Automation Automation in Biopharmaceutical Product Introduction
  • 7.7.4 Peak Analysis and Automation Response to COVID-19 and Related Developments
• 7.8 Waters
  • 7.8.1 Waters Business Overview
  • 7.8.2 Waters Automation in Biopharmaceutical Quarterly Revenue, 2020
  • 7.8.3 Waters Automation in Biopharmaceutical Product Introduction
  • 7.8.4 Waters Response to COVID-19 and Related Developments
• 7.9 Capsugel
  • 7.9.1 Capsugel Business Overview
  • 7.9.2 Capsugel Automation in Biopharmaceutical Quarterly Revenue, 2020
  • 7.9.3 Capsugel Automation in Biopharmaceutical Product Introduction
  • 7.9.4 Capsugel Response to COVID-19 and Related Developments
• 7.10 RheoSense
  • 7.10.1 RheoSense Business Overview
  • 7.10.2 RheoSense Automation in Biopharmaceutical Quarterly Revenue, 2020
  • 7.10.3 RheoSense Automation in Biopharmaceutical Product Introduction
  • 7.10.4 RheoSense Response to COVID-19 and Related Developments
• 7.11 Eirechrom
  • 7.11.1 Eirechrom Business Overview
  • 7.11.2 Eirechrom Automation in Biopharmaceutical Quarterly Revenue, 2020
  • 7.11.3 Eirechrom Automation in Biopharmaceutical Product Introduction
  • 7.11.4 Eirechrom Response to COVID-19 and Related Developments
• 7.12 BioProcess International
  • 7.12.1 BioProcess International Business Overview
  • 7.12.2 BioProcess International Automation in Biopharmaceutical Quarterly Revenue, 2020
  • 7.12.3 BioProcess International Automation in Biopharmaceutical Product Introduction
  • 7.12.4 BioProcess International Response to COVID-19 and Related Developments
• 7.13 Novasep
  • 7.13.1 Novasep Business Overview
  • 7.13.2 Novasep Automation in Biopharmaceutical Quarterly Revenue, 2020
  • 7.13.3 Novasep Automation in Biopharmaceutical Product Introduction
  • 7.13.4 Novasep Response to COVID-19 and Related Developments

8 Key Findings

9 Appendix

• 9.1 About US